» Articles » PMID: 31485645

Silencing of MALAT1 Inhibits Migration and Invasion by Sponging MiR‑1‑3p in Prostate Cancer Cells

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2019 Sep 6
PMID 31485645
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer is a common malignancy with a high mortality rate. Long non‑coding RNA metastasis associated with lung adenocarcinoma transcript 1 (MALAT1) has been reported to serve tumor‑promoting roles. However, the underlying mechanism requires further examination. In the present study, it was demonstrated that MALAT1 was increased while microRNA (miR/miRNA)‑1‑3p was decreased in prostate cancer cell lines. The silencing of MALAT1 inhibited migration, invasion and epithelial‑mesenchymal transition, when epithelial (E)‑cadherin expression level was increased, and neural (N)‑cadherin, vimentin, Slug and Snail expression levels were decreased. Dual‑luciferase reporter assay results demonstrated that miR‑1‑3p bound to MALAT1 and coronin 1C (CORO1C) 3' untranslated region, and MALAT1 competed with CORO1C for the binding sites of miR‑1‑3p. MALAT1 inhibited the expression of miR‑1‑3p and vice versa. MALAT1 knockdown induced the decline of CORO1C, which was subsequently recovered by the miR‑1‑3p inhibitor. In addition, by inhibiting miR‑1‑3p or overexpressing CORO1C, the silencing of MALAT1‑induced phenotypic alterations were restored. In conclusion, MALAT1 serving as a degradable miRNA sponge, may sequester miR‑1‑3p from CORO1C and by silencing MALAT1, migration, invasion and epithelial‑mesenchymal transition may be inhibited in prostate cancer cells. MALAT1 and CORO1C may serve as novel clinical therapeutic targets for prostate cancer.

Citing Articles

Natural products and long non-coding RNAs in prostate cancer: insights into etiology and treatment resistance.

Elimam H, Zaki M, Abd-Elmawla M, Darwish H, Hatawsh A, Aborehab N Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39825964 DOI: 10.1007/s00210-024-03736-x.


Broadening horizons: molecular mechanisms and disease implications of endothelial-to-mesenchymal transition.

Qian C, Dong G, Yang C, Zheng W, Zhong C, Shen Q Cell Commun Signal. 2025; 23(1):16.

PMID: 39789529 PMC: 11720945. DOI: 10.1186/s12964-025-02028-y.


TMED3 promotes prostate cancer via FOXO1a and FOXO3a phosphorylation.

Wei X, Liang J, Huang H, Yang D, Wang X, Wang X Oncol Res. 2024; 33(1):161-169.

PMID: 39735675 PMC: 11671412. DOI: 10.32604/or.2024.048054.


LncRNA LOC730101 Promotes Darolutamide Resistance in Prostate Cancer by Suppressing miR-1-3p.

Zhou T, Nguyen S, Wu J, He B, Feng Q Cancers (Basel). 2024; 16(14).

PMID: 39061232 PMC: 11274508. DOI: 10.3390/cancers16142594.


Cancer fusion transcripts with human non-coding RNAs.

Mohammad T, Zolotovskaia M, Suntsova M, Buzdin A Front Oncol. 2024; 14:1415801.

PMID: 38919532 PMC: 11196610. DOI: 10.3389/fonc.2024.1415801.


References
1.
Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

2.
Humphries C, Balcer H, DAgostino J, Winsor B, Drubin D, Barnes G . Direct regulation of Arp2/3 complex activity and function by the actin binding protein coronin. J Cell Biol. 2002; 159(6):993-1004. PMC: 2173993. DOI: 10.1083/jcb.200206113. View

3.
Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider P . MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003; 22(39):8031-41. DOI: 10.1038/sj.onc.1206928. View

4.
Van Bokhoven A, Varella-Garcia M, Korch C, Johannes W, Smith E, Miller H . Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003; 57(3):205-25. DOI: 10.1002/pros.10290. View

5.
Vicente-Manzanares M, Webb D, Horwitz A . Cell migration at a glance. J Cell Sci. 2005; 118(Pt 21):4917-9. DOI: 10.1242/jcs.02662. View